Archive: Company News
Company News: Nature Publication Reports Favorable Clinical Trial Results of BioNTech’s Individualized Cancer Vaccine IVAC® MUTANOME
– First-ever clinical study demonstrates personalized RNA-based vaccine using mutant neo-epitopes as antigens activates immune system against individual mutations and exerts anti-cancer activity –
BioNTech AG, a fully-integrated biotechnology company pioneering individualized cancer immunotherapy, today announced Phase I trial results demonstrating its IVAC® MUTANOME, an individualized RNA vaccine based on patient-specific mutations, induces strong immunogenicity as well as promising anti-tumor activity in high-risk patients with late-stage melanoma.
Company News: Agena Bioscience Launches CE-IVD System For Hospitals And Diagnostic Laboratories In Europe
– MassARRAY® System with Chip Prep Module receives CE-IVD marking for general in vitro diagnostic use in Europe
Agena Bioscience today announced the European launch of the MassARRAY® System with CHIP Prep Module (CPM), marketed as a CE-IVD product under the Directive 98/79/EC for in vitro diagnostic medical devices.
Company News: “GEAR – Predicting Antibiotic Resistances with Genetic Data” Succeeds in Competition “Landmarks in the Land of Ideas”
Ares Genetics GmbH, a wholly-owned subsidiary of Curetis GmbH and a developer of pioneering solutions for the detection of genetic resistances in pathogens, today announced that the project “GEAR – Predicting Antibiotic Resistances with Genetic Data” has been awarded in the competition “Landmarks in the Land of Ideas”.
Company News: Curetis Reports Results of the Annual Shareholder Meeting Held on June 23, 2017
– Dr. Nils Clausnitzer elected as member of the Supervisory Board
Curetis N.V. (the “Company” and, together with Curetis GmbH, “Curetis“), a developer of next-level molecular diagnostic solutions, today reported the results of its Annual Shareholder Meeting (“AGM”) held in Amsterdam on June 23, 2017.